



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

**GENEGO'S METACORE™ SOFTWARE APPLICATION ACHIEVES
GENECHIP-COMPATIBLE™ STATUS WITH AFFYMETRIX' GENECHIP®
MICROARRAY PLATFORM**

MetaCore for easy, intuitive visualization and analysis of expression data on pathways and networks

St Joseph, MI, September 19th , 2005 – GeneGo today announced that its MetaCore software application has achieved GeneChip-compatible™ status with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has joined the Affymetrix GeneChip-compatible™ Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible software provider, GeneGo is committed to seamlessly integrating its MetaCore platform with the Affymetrix GeneChip platform.

MetaCore has worked with Affymetrix probe IDs since the product's launch in March 2004, alongside with a number of other conventional identifiers. Upon parsing, microarray expression data is visualized and analyzed in the context of pathways, biological networks and cellular processes, using the manually curated knowledge base of over 4.5 million findings. MetaCore supports parsing species specific arrays for human, rat, mouse, yeast, worm, fly and chicken, as well as specialty arrays such as Affymetrix tox chips. MetaCore also has the unique ability to visualize multiple gene expression, genetic and proteomic data sets concurrently.

“Affymetrix is a clear market leader in microarray technology and we make it a priority that our products work seamlessly with the content of their GeneChip microarrays. Currently, we map more Affymetrix probes on pathways and networks than any other data mining platform” said Julie Bryant Vice President of Business Development. “We work in close contact with the Affymetrix team to keep on top of their development and new products”.

“Pathway analysis and annotation represents a critical link between microarray data and biomedical utility.” Said Steve Lincoln, Vice President of Informatics at Affymetrix. “We are pleased to be working with GeneGo in integrating our platforms, allowing our mutual customers to get the most from their GeneChip data.”

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.

About the Affymetrix Developers Network

Through one of the largest third-party software developer communities within the life science industry, Affymetrix works with ADN participants to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information on the ADN Program please visit www.affymetrix.com/genechip/developer. Visit the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible.

About Affymetrix:

Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix GeneChip technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on a microarray, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com.